<span id="midArticle_start"/> GW Pharmaceuticals Plc :
<span id="midArticle_0"/>* Initiates second phase 3 pivotal study of Epidiolex (CBD)in Lennox-Gastaut syndrome
<span id="midArticle_1"/> <span class="first-article-divide"/>* Announced plans to develop Epidiolex in a third targetindication, tuberous sclerosis complex, a rare pediatric geneticdisorder
<span id="midArticle_2"/> <span class="second-article-divide"/>* Expects to commence a TSC phase-3 clinical program insecond half of 2015
<span id="midArticle_3"/> <span class="third-article-divide"/>* Anticipates that top-line data from this trial will beavailable in Q1 of 2016Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Initiates second phase 3 pivotal study of Epidiolex (CBD)in Lennox-Gastaut syndrome
<span id="midArticle_1"/> <span class="first-article-divide"/>* Announced plans to develop Epidiolex in a third targetindication, tuberous sclerosis complex, a rare pediatric geneticdisorder
<span id="midArticle_2"/> <span class="second-article-divide"/>* Expects to commence a TSC phase-3 clinical program insecond half of 2015
<span id="midArticle_3"/> <span class="third-article-divide"/>* Anticipates that top-line data from this trial will beavailable in Q1 of 2016Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1L368R2
No comments:
Post a Comment